Morgan Stanley Maintains Overweight on Legend Biotech, Lowers Price Target to $48
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $49 to $48.
Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $49 to $48.